IPO registrations (S-1, F-1) · Registrants
Icosavax, Inc.
- SEC CIK
- 1786255 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-07-07, last 2021-07-22; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2021-07-30; declared effective 2021-07-28
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 1930 BOREN AVE., SUITE 1000, Seattle, WA 98101
- EDGAR entity type
- operating
- Insiders and CEO pay
- Icosavax, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2021-07-22)
- Final price
- $15.00 per share, within the range (424B4 filed 2021-07-30, an initial public offering)
- Shares sold
- 12,133,333
- Gross proceeds
- $181,999,995 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ICVX
- Lead underwriters
- Jefferies; Cowen (3,458,000 shares); Evercore (2,972,667 shares); William Blair (1,334,666 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Icosavax, Inc. Fuzzy (name and state)
- Business registration: Icosavax, Inc. Fuzzy (name and state)
- Form D issuer: Icosavax, Inc. EXACT (CIK (EXACT))
- SEC filer: Icosavax, Inc. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-07-07 | S-1 | S-1 (registration) | Icosavax, Inc. | 0001193125-21-209031 ↗ |
| 2021-07-22 | S-1/A | S-1/A (amendment) | Icosavax, Inc. | 0001193125-21-221834 ↗ |
| 2021-07-28 | S-1MEF | S-1MEF (added securities) | Icosavax, Inc. | 0001193125-21-227732 ↗ |
| 2021-07-28 | EFFECT | EFFECT (declared effective) | Icosavax, Inc. | 9999999995-21-002961 ↗ |
| 2021-07-30 | 424B4 | 424B4 (final prospectus) | Icosavax, Inc. | 0001193125-21-229444 ↗ |
| 2022-08-29 | EFFECT | EFFECT (declared effective) | Icosavax, Inc. | 9999999995-22-002540 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-22 | S-1/A | registration statement | $14.00–$16.00 | 10,000,000 | - | Nasdaq ICVX | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2021-07-30 | 424B4 | final prospectus | $15.00 | 12,133,333 | $181,999,995 | Nasdaq ICVX | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ADAMS STREET PARTNERS LLC | Other; TenPercentOwner | 2 | 2021 | ||
| Cearley Cassia | Officer; Other | Chief Business Officer | 18 | 2021–2024 | |
| Chen Bihua | Other; TenPercentOwner | 2 | 2021 | ||
| Cormorant Asset Management, LP | Other; TenPercentOwner | 2 | 2021 | ||
| Cormorant Global Healthcare Master Fund, LP | Other; TenPercentOwner | 2 | 2021 | ||
| Cormorant Private Healthcare Fund III LP | Other; TenPercentOwner | 2 | 2021 | ||
| FIELDS HEIDI | Director; Other | 5 | 2021–2024 | ||
| Gould Terry P | Director; Director,TenPercentOwner | 2 | 2021 | ||
| Holtzman Douglas | Officer | Chief Scientific Officer | 11 | 2021–2023 | |
| Kanesa-thasan Niranjan | Officer; Other | Chief Medical Officer | 13 | 2021–2024 | |
| Kolchinsky Peter | Director,TenPercentOwner | 6 | 2021–2024 | ||
| MCDADE MARK | Director; Other; TenPercentOwner | 6 | 2021–2024 | ||
| NanoDimension III GP Limited Partnership | Other; TenPercentOwner | 2 | 2021 | ||
| NanoDimension III, L.P. | Other; TenPercentOwner | 2 | 2021 | ||
| NanoDimension III Management Ltd | Other; TenPercentOwner | 2 | 2021 | ||
| Nicholson Jonathan | Other; TenPercentOwner | 2 | 2021 | ||
| Qiming U.S. Healthcare Fund II, L.P. | Director,TenPercentOwner; Other | 2 | 2021 | ||
| Qiming U.S. Healthcare GP II, LLC | Other; TenPercentOwner | 2 | 2021 | ||
| RA Capital Healthcare Fund LP | Director,TenPercentOwner | 6 | 2021–2024 | ||
| RA CAPITAL MANAGEMENT, L.P. | Director,TenPercentOwner | 6 | 2021–2024 | ||
| RA Capital Nexus Fund II, L.P. | Director,TenPercentOwner | 5 | 2021–2024 | ||
| Richardson Charles E | Officer | See Remarks; SVP, Technical Operations | 5 | 2021–2022 | |
| Russo Thomas Joseph | Officer; Other | Chief Financial Officer | 11 | 2021–2024 | |
| Sanofi | TenPercentOwner | 2 | 2021 | ||
| Shah Rajeev M. | Director,TenPercentOwner | 6 | 2021–2024 | ||
| Simpson Adam K. | Director,Officer; Other | Chief Executive Officer | 20 | 2021–2024 | |
| Veneman Ann M | Director; Other | 5 | 2021–2024 | ||
| Yamada Tadataka | Director | 1 | 2021 | ||
| Bekiroglu Elizabeth | Officer | General Counsel & Corp. Sec.; See Remarks | 6 | 2021–2023 | |
| Shiver John W. | Director; Other | 5 | 2022–2024 | ||
| Wassil Jim | Director; Other | 4 | 2022–2024 | ||
| RA Capital Nexus Fund, L.P. | Director,TenPercentOwner | 1 | 2023 | ||
| Khan Amin | Officer; Other | EVP, Head of Research & Dev. | 3 | 2023–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-04-07 | Icosavax, Inc. | Biotechnology | $99,729,701 | $99,729,701 | 36 | 1 |
| 2019-10-18 | Icosavax, Inc. | Biotechnology | $51,007,373 | $30,007,376 | 22 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Icosavax, Inc. | WA | State business registries | name and state |
| Business registration | Icosavax, Inc. | WA | State business registries | name and state |
| Form D issuer | Icosavax, Inc. | WA | Form D private offerings | CIK (EXACT) |
| Patent assignee | ICOSAVAX, INC. | WA | Patents (USPTO) | name and state |
| SEC filer | Icosavax, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Icosavax, Inc. | WA | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), WA first:
- CORIXA CORP WA
- Seagen Inc. WA
- ZYMOGENETICS INC WA
- NS Wind Down Co., Inc. WA
- Adaptive Biotechnologies Corp WA
- Juno Therapeutics, Inc. WA
- LeonaBio, Inc. WA
- Sana Biotechnology, Inc. WA
- Intrinsic Medicine, Inc. WA
- Aurion Biotech, Inc. WA
In other datasets, the same topic (Health) in WA:
- Nonprofit: ACUPUNCTURE RELIEF PROJECT (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health